NPPB and diabetes mellitus: The effect of empagliflozin on the primary outcome was similar in subgroups by sex, diabetes status, and across the spectrum of NT-proBNP and eGFR studied (P values for heterogeneity or trend >0.3, Figure 3 and Supplemental Table 5).